Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection - Scorecard - MDSpire
Advertisement
Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection
Clinical Scorecard: Analysis of Gastrointestinal Microbiome and Bile Acid Composition in Patients Experiencing Initial or Recurrent Clostridioides difficile Infections
At a Glance
Category
Detail
Condition
Clostridioides difficile infection (CDI), including first and multiply recurrent infections
Key Mechanisms
Low microbial diversity and altered bile acid profiles (elevated primary bile acids and depleted secondary bile acids) favor C. difficile spore germination and toxin production, increasing recurrence risk
Target Population
Adults ≥18 years with first or multiply recurrent CDI following antibacterial treatment
Care Setting
Outpatient or inpatient settings following standard-of-care antibiotic treatment
Key Highlights
Baseline microbial diversity is similarly low in patients with first and multiply recurrent CDI.
Treatment with fecal microbiota spores, live-brpk (VOWST®; VOS) increases microbial diversity and secondary bile acids while decreasing primary bile acids, reducing recurrence risk.
Antibiotics alone do not restore microbiome balance and may promote recurrence; microbiome therapeutics offer a durable clinical response.
Guideline-Based Recommendations
Diagnosis
Identify CDI episodes and classify as first or recurrent based on clinical history.
Management
Use standard-of-care antibiotics to treat active CDI symptoms.
Consider FDA-approved microbiome therapeutics (VOWST®, REBYOTA®) after second recurrence or earlier in high-risk patients to prevent recurrence.
Alternative antibiotics, bezlotoxumab, and pulse-taper regimens may be used per guidelines.
Avoid unapproved fecal microbiota transplantation due to infection transmission risks.
Monitoring & Follow-up
Monitor for CDI recurrence up to 8 weeks post-treatment.
Assess clinical response and consider microbiome restoration strategies if recurrence risk is high.
Risks
Antibiotic treatment alone may exacerbate microbiome disruption and increase recurrence risk.
Unapproved fecal microbiota transplantation carries risk of transmitting infectious agents.
Patient & Prescribing Data
Adults with first or multiply recurrent CDI treated with antibiotics followed by VOWST®
VOWST® treatment following antibiotics results in low recurrence rates (~6.5% in first recurrence, ~9.7% in multiply recurrent) and is well tolerated.
Clinical Best Practices
Recognize the role of microbiome disruption and bile acid imbalance in CDI pathogenesis and recurrence.
Incorporate microbiome therapeutics post-antibiotic treatment to restore microbial diversity and bile acid balance.
Tailor treatment strategies based on recurrence history and patient risk factors.
by Jessica A Bryant, Timothy J Straub, Darrell S Pardi, Kevin D Litcofsky, Colleen R Kelly, Meghan E Chafee, Stuart H Cohen, Sahil Khanna, Charles S Berenson, Jennifer Wortman, Matthew Sims, Christopher B Ford, Mary-Jane Lombardo, Barbara H McGovern, Lisa von Moltke, Colleen S Kraft, Matthew R Henn, Brooke R Hasson
